Osmetech Change to GenMark Gets OK from UK Court | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Osmetech announced over the weekend that the High Court of Justice in England and Wales has sanctioned the company's plan to float in the US and the Capital Reduction by which GenMark's purchase of Osmetech is being implemented.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.